Item 1.01. Entry into a Material Definitive Agreement.

On December 17, 2020, Greenwich LifeSciences, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Aegis Capital Corp., acting as the representative (the "Representative") of the several underwriters (the "Underwriters") named therein, with respect to an underwritten public offering (the "Offering") of 660,000 shares (the "Shares") of the Company's common stock, par value $0.001 per share (the "Common Stock"), at a public offering price of $40.00 per Share. The Company has also granted the Representative a 45-day option to purchase up to 99,000 additional shares of Common Stock to cover over-allotments.

The Shares were offered by the Company pursuant to a registration statement on Form S-1 (File No. 333-251366) previously filed with the U.S. Securities and Exchange Commission (the "SEC") and subsequently declared effective on December 17, 2020 and a registration statement on Form S-1 (File No. 333-251438) previously filed with the SEC on December 17, 2020 and immediately declared effective. The Offering closed on December 22, 2020.

The gross proceeds to the Company from the Offering, before deducting underwriting discounts and commissions and other estimated Offering expenses was $26.4 million. The Company intends to use the net proceeds from the Offering

for completion of all manufacturing and all clinical trial activities to complete an interim analysis and data readout of the GP2 Phase III clinical trial, for the submission of a Biologics Licensing Application to the FDA seeking conditional marketing approval of GP2, for the in-licensing or acquisition and development of additional products, including the coronavirus vaccine program, and for working capital and general corporate purposes.

The Underwriting Agreement contains customary representations, warranties, covenants and agreements by the Company, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. Certain of the Company's directors and executive officers have agreed, subject to certain exceptions, not to sell, transfer or dispose any shares of Common Stock for six months, and the Company has agreed not to sell or transfer any shares of Common Stock for six months, without first obtaining the written consent of the Representative.

The Underwriters and their affiliates have, from time to time, provided and may in the future provide, various investment banking and other financial services for us for which they may receive customary fees.

The foregoing description of the Underwriting Agreement is not complete, is subject to and qualified in its entirety by reference to the Underwriting Agreement, a copy of which is attached hereto as Exhibit 1.1 and is incorporated herein by reference.




Item 8.01. Other Events.

On December 18, 2020, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated herein by reference.

On December 22, 2020, the Company issued a press release announcing the closing of the Offering. A copy of the press release is attached as Exhibit 99.2 hereto and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit No.   Description
1.1             Underwriting Agreement, dated December 17, 2020
99.1            Pricing Press Release, dated December 18, 2020
99.2            Closing Press Release, dated December 22, 2020

© Edgar Online, source Glimpses